Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > How Barclays Capital values Small Cap Oncology names

<< Previous

Bullboard Posts

Next >>

Comment by Wino115on Feb 04, 2021 9:02am

88 Views

Post# 32468630

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:How Barclays Capital values Small Cap Oncology names

This is the kind of thing they should call around to all the business publications in Us and Can and explain the importance and offer to do a story on how this peptide, discovered as a side project to a bigger one looking for ways to penetrate the blood brain barrier and ignored until THTX picked it up for nothing because the CMO saw something in the science and the CEO saw a good deal in the offing, is now a lead oncology candidate with a novel peptide conjugate approach which has many advantages over antibody conjugate approaches. Pitch the platform, the uniqueness of the receptor, the possibilities on VM, the wide applicability, etc.. and how this small company took a small Univ Montreal lab project and has quickly ramped it up to a leading PDC candidate that the FDA has now fast tracked. I mean, turn this thing into a real story about having solid scientists, a keen acquisitive eye, and now you are leading the pack in PDCs that happens to work on tumors that have proven unbelievably hard to attack.

Pitch it Leah -- they have that PR guy on staff to that reads the regulatory cr@p on calls -- go call all your sources to get some solid PR out of this. Bloomberg loves these kind of stories and is always desperately in need of stories. Their reporters are ranked on whether their stories move stocks. This one would. The WSJ would also bite at a story like that. Put the elevator pitch together Leah and call around to all the newsies.

Capitalize on this. Don't just let it fade. Give it some runway.....

scarlet1967 wrote: Yes we will have a free runway for SP to appreciate also more oncology investors going forward.

palinc2000 wrote:
It does not need to hold but at least the Buyers of the Units with a short term perspective will hopefully all exit today and this will be the start of a new momentum

scarlet1967 wrote: I agree with wino I don't think it will hold on these levels unfortunately but it might get ride of the residual shorts from last offering and maybe more.
Hopefully some double digit gains today plus good publicity and a base for SP to move upward going forward.